Insider Profile
Hasker, Stephen John
1
Companies Filed At
9
Open-Market Buys (2yr)
$300K
Buy Value (2yr, open-market)
Mar 10, 2026
Most Recent Trade
40
Credibility
Score
79%
Hit Rate
+3.4%
Avg 90d Return
+7.2%
Median 90d Return
14
Evaluated Trades
+14.9%
Best Trade
-19.8%
Worst Trade
Hit rate and returns are based on 14 open-market buys with evaluable 90-day outcomes. Score reflects historical conviction, not a guarantee of future performance. Limited signal — either below-average timing or insufficient trade history.
Cross-Company Track Record
Hit Rate · 90d
-24.3%
Median Alpha · 90d
9
Closed Buys Evaluated
0%
Beat XIU
All-insider base rate: 59% hit rate  · +1.3% mean alpha (n=11504)
cluster buyer high frequency size concentrated
Entry: closing price on SEDI filing date (point-in-time). Exit: 90 calendar days later. Alpha vs XIU.TO (iShares TSX 60). Closed trades only. Not investment advice.
Research 9 closed buys with individual return outcomes available on the Research plan.
Date Company Role Nature Dir. Shares Price Value Score
Mar 10, 2026 $TRI
Thomson Reuters Corp
President & CEO Exercise Buy 6,968 58
Mar 10, 2026 $TRI
Thomson Reuters Corp
President & CEO Plan / DRIP Buy 547 58
Mar 10, 2026 $TRI
Thomson Reuters Corp
President & CEO Exercise Buy 6,968 58
Mar 10, 2026 $TRI
Thomson Reuters Corp
President & CEO Exercise Sell 14,302 58
Mar 10, 2026 $TRI
Thomson Reuters Corp
President & CEO Comp. Grant Buy 5,685 58
Mar 10, 2026 $TRI
Thomson Reuters Corp
President & CEO Exercise Sell 48,412 58
Mar 10, 2026 $TRI
Thomson Reuters Corp
President & CEO Exercise Buy 23,587 58
Mar 10, 2026 $TRI
Thomson Reuters Corp
President & CEO Exercise Sell 14,302 58
Mar 06, 2026 $TRI
Thomson Reuters Corp
President & CEO Open Market Buy 14 $109.76 $2K 58
Mar 06, 2026 $TRI
Thomson Reuters Corp
President & CEO Open Market Buy 2,169 $109.77 $238K 58
Mar 06, 2026 $TRI
Thomson Reuters Corp
President & CEO Open Market Buy 100 $109.67 $11K 58
Mar 06, 2026 $TRI
Thomson Reuters Corp
President & CEO Open Market Buy 50 $109.68 $5K 58
Mar 06, 2026 $TRI
Thomson Reuters Corp
President & CEO Open Market Buy 100 $109.69 $11K 58
Mar 06, 2026 $TRI
Thomson Reuters Corp
President & CEO Open Market Buy 46 $109.70 $5K 58
Mar 06, 2026 $TRI
Thomson Reuters Corp
President & CEO Open Market Buy 152 $109.71 $17K 58
Mar 06, 2026 $TRI
Thomson Reuters Corp
President & CEO Open Market Buy 102 $109.72 $11K 58
Mar 06, 2026 $TRI
Thomson Reuters Corp
President & CEO Open Market Buy 1 $109.74 $110 58
Mar 04, 2026 $TRI
Thomson Reuters Corp
President & CEO Comp. Grant Buy 56,624 58
Dec 31, 2025 $TRI
Thomson Reuters Corp
President & CEO Plan / DRIP Buy 523 58
Sep 30, 2025 $TRI
Thomson Reuters Corp
President & CEO Plan / DRIP Buy 399 58
Jun 30, 2025 $TRI
Thomson Reuters Corp
President & CEO Plan / DRIP Buy 350 58
Mar 14, 2025 $TRI
Thomson Reuters Corp
President & CEO Buyback Buy 331 58
Mar 14, 2025 $TRI
Thomson Reuters Corp
President & CEO Exercise Sell 49,561 58
Mar 14, 2025 $TRI
Thomson Reuters Corp
President & CEO Exercise Buy 24,153 58
Mar 10, 2025 $TRI
Thomson Reuters Corp
President & CEO Plan / DRIP Buy 326 $173.74 $57K 58
Dec 10, 2024 $TRI
Thomson Reuters Corp
President & CEO Plan / DRIP Buy 409 $170.17 $70K 58
Sep 10, 2024 $TRI
Thomson Reuters Corp
President & CEO Plan / DRIP Buy 402 $170.74 $69K 58
Jun 10, 2024 $TRI
Thomson Reuters Corp
President & CEO Plan / DRIP Buy 404 $170.74 $69K 58
Mar 06, 2024 $TRI
Thomson Reuters Corp
President & CEO Comp. Grant Buy 53,280 $156.94 $8.4M 58
Mar 06, 2024 $TRI
Thomson Reuters Corp
President & CEO Comp. Grant Buy 24,382 58
Mar 06, 2024 $TRI
Thomson Reuters Corp
President & CEO Comp. Grant Buy 12,191 58
Dec 15, 2023 $TRI
Thomson Reuters Corp
President & CEO Plan / DRIP Buy 520 $138.85 $72K 58
Sep 15, 2023 $TRI
Thomson Reuters Corp
President & CEO Plan / DRIP Buy 554 $129.90 $72K 58
Jun 15, 2023 $TRI
Thomson Reuters Corp
President & CEO Plan / DRIP Buy 556 $128.38 $71K 58
Muted rows are plan purchases, compensation grants, or DRIP — not open-market. Confluence Scores reflect the company's current score, not the score at time of trade.
Form55 provides data and analysis for informational purposes only. Nothing on this site constitutes investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.